Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue. Amneal announced that it plans to expand into high growth areas including biosimilars and injectables.
Permit Required: Full Court Denies Access to Costs Appeal in Carpark Patent Saga
Vehicle Monitoring Systems Pty Limited v SARB Management Group Pty Ltd trading as Database Consultants Australia (Costs) [2024] FCAFC 155 ...